Nexell gets $4.3 million in Baxter deal
This article was originally published in Clinica
Baxter is to pay $4.3 million for certain assets and liabilities of Nexell Therapeutics' cell processing business, as well as worldwide sales, marketing and distribution rights to related products. It will also get royalties on future product sales. Baxter, which owns around 38% of Nexell, will offer certain Nexell workers positions at Baxter.
You may also be interested in...
To be more transparent and allow more public discourse, the HHS now requires all its agencies to publish documents it uses to rationalize proposed rules and demonstration projects.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.